-
公开(公告)号：US20250000877A1
公开(公告)日：2025-01-02
申请号：US18708357
申请日：2022-10-28
Applicant: SHAPERON INC. , SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Inventor： Seung Yong SEONG
IPC: A61K31/575 , A61P31/16
Abstract: The present invention relates to a composition for preventing or treating virus infection diseases containing taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient. Specifically, inflammatory cells and inflammatory cytokines were found to decrease in the lungs of an influenza virus-infected animal model to which taurodeoxycholic acid or a pharmaceutically acceptable salt thereof was administered as an inflammasome inhibitor, and thus the inflammasome inhibitor containing taurodeoxycholic acid or a pharmaceutically acceptable salt thereof can be used as an active ingredient in the composition for preventing or treating virus infection diseases.
-
公开(公告)号：US20240132588A1
公开(公告)日：2024-04-25
申请号：US18277914
申请日：2022-02-21
Applicant: SHAPERON INC. , SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Inventor： Seung Yong SEONG , Sang Beum LEE
CPC classification number: C07K16/2803 , A61K47/6813 , A61K47/6849 , A61P35/00 , G01N33/68 , C07K2317/31 , C07K2317/569 , G01N2333/70503
Abstract: The present invention relates to a single domain antibody against CD47 and uses thereof. Specifically, a single domain antibody that specifically binds to CD47, an immune checkpoint protein, has been constructed and its affinity for an immune antigen and antitumor effect have been verified, so the single domain antibody can be usefully used as an immune checkpoint inhibitor in cancer immunotherapy.
-
公开(公告)号：US20230366875A1
公开(公告)日：2023-11-16
申请号：US18027027
申请日：2021-08-23
Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION , SHAPERON INC.
Inventor： Seung Yong SEONG
CPC classification number: G01N33/5041 , G01N33/6845 , G01N33/6872 , G01N2333/705
Abstract: The present invention relates to a GPCR19-P2Xn receptor complex and use of the same, particularly to a method for screening a substance that regulates the interaction between GPCR19 and a P2Xn receptor in their complex; a method for screening a substance for prevention or treatment of an NLRP3 inflammasome-associated diseases utilizing the interaction between GPCR19 and a P2Xn receptor in their complex; and a method for preventing or treating an NLRP3 inflammasome-associated disease, which comprises administering to an individual a pharmaceutically effective amount of a substance that induces the interaction between GPCR19 and a P2Xn receptor in their complex.
-
公开(公告)号：US20210386761A1
公开(公告)日：2021-12-16
申请号：US17284305
申请日：2020-01-23
Applicant: SHAPERON INC.
Inventor： Seung-Yong SEONG , Sang-Uk SEO , Bolormaa MUNKHBILEG
IPC: A61K31/575 , A61P1/00 , A61P37/06 , A23L33/00 , A23L33/10
Abstract: The present invention relates to a composition for prevention or treatment of inflammatory bowel disease, which contains taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient. Specifically, taurodeoxycholic acid and a pharmaceutically acceptable salt thereof can be used as an active ingredient of a composition for prevention or treatment of inflammatory bowel disease since it has been confirmed that the clinical symptoms and histopathological symptoms caused by inflammatory bowel disease are alleviated and the increase in inflammatory cells in bowels and the production of pro-inflammatory cytokines are suppressed by using a salt of taurodeoxycholic acid.
-
公开(公告)号：US20240228622A9
公开(公告)日：2024-07-11
申请号：US18277926
申请日：2022-02-21
Applicant: SHAPERON INC. , SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Inventor： Seung Yong SEONG , Sang Beum LEE
CPC classification number: C07K16/2827 , A61K47/6849 , A61P35/00 , G01N33/68 , A61K2039/505 , C07K2317/35 , C07K2317/569
Abstract: The present invention relates to a single domain antibody against PD-L1 and uses thereof. Specifically, a single domain antibody that specifically binds to PD-L1, an immune checkpoint protein, has been constructed and its affinity for an immune antigen and antitumor effect have been verified, so the single domain antibody can be usefully used as an immune checkpoint inhibitor in cancer immunotherapy.
-
Patent Agency Ranking
公开(公告)号：US20240132594A1
公开(公告)日：2024-04-25
申请号：US18277926
申请日：2022-02-21
Applicant: SHAPERON INC. , SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Inventor： Seung Yong SEONG , Sang Beum LEE
CPC classification number: C07K16/2827 , A61K47/6849 , A61P35/00 , G01N33/68 , A61K2039/505 , C07K2317/35 , C07K2317/569
Abstract: The present invention relates to a single domain antibody against PD-L1 and uses thereof. Specifically, a single domain antibody that specifically binds to PD-L1, an immune checkpoint protein, has been constructed and its affinity for an immune antigen and antitumor effect have been verified, so the single domain antibody can be usefully used as an immune checkpoint inhibitor in cancer immunotherapy.
-
公开(公告)号：US20230331766A1
公开(公告)日：2023-10-19
申请号：US18026888
申请日：2021-08-23
Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION , SHAPERON INC.
Inventor： Seung Yong SEONG
IPC: C07J41/00
CPC classification number: C07J41/0061
Abstract: The present invention relates to a mass production method of sodium taurodeoxycholate having low impurity and few by-products, in which the procedure of process is simplified since isopropyl alcohol is used and separation and purification is performed through batch washing for commercial production of sodium taurodeoxycholate.
-
公开(公告)号：US20250134910A1
公开(公告)日：2025-05-01
申请号：US18694190
申请日：2022-09-15
Applicant: SHAPERON INC.
Inventor： Seung Yong SEONG
IPC: A61K31/575 , A61K45/06 , A61P31/14
Abstract: The present invention relates to a composition for treating coronavirus infection-19 (COVID-19), comprising taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof and an antiviral agent as active ingredients, it was confirmed that clinical symptoms were cured in patients with COVID-19 pneumonia who were administered a combination of a pharmaceutically acceptable salt of taurodeoxycholic acid as an inflammasome inhibitor and an antiviral agent, and thus this combination of taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an inflammasome inhibitor and an antiviral agent, holds promise as active ingredients in compositions for the prevention or treatment of lower respiratory tract infectious diseases, including COVID-19.
-
公开(公告)号：US20250099487A1
公开(公告)日：2025-03-27
申请号：US18906683
申请日：2024-10-04
Applicant: SHAPERON INC.
Inventor： Seung Yong SEONG , Jeong Jung HWANG
IPC: A61K31/575 , A61P11/00
Abstract: The present invention relates to a composition for the prevention or treatment of pulmonary fibrosis, comprising a pharmaceutically acceptable salt of taurodeoxycholic acid as an active ingredient. Specifically, it has been confirmed that administration of a pharmaceutically acceptable salt of taurodeoxycholic acid results in a reduction of pulmonary fibrosis and the expression of pulmonary fibrosis-related factors in both an idiopathic pulmonary fibrosis animal model and a pulmonary fibrosis cell model. Therefore, taurodeoxycholic acid or a pharmaceutically acceptable salt thereof can be utilized as an active ingredient in a composition for the prevention or treatment of pulmonary fibrosis.
-
公开(公告)号：US20250084170A1
公开(公告)日：2025-03-13
申请号：US18951146
申请日：2024-11-18
Applicant: SHAPERON INC. , SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Inventor： Seung Yong SEONG , Sang Beum LEE , Jeong Hwan KIM
Abstract: The present invention relates to a bispecific humanized single domain antibody targeting both PD-L1 and CD47, as well as uses thereof. Specifically, a humanized single domain antibody that binds bispecifically to PD-L1 and CD47, which are immune checkpoint proteins, has been developed, and its efficacy has been confirmed both in vitro and in vivo. Therefore, the bispecific humanized single domain antibody can be effectively used as an immune checkpoint inhibitor for immuno-oncology therapy.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.012 seconds)
